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Summary
 
Unmutated tumor antigens are chosen as primary candidates for tumor vaccine because of their
expression on multiple lineages of tumors. A critical issue is whether unmutated tumor antigens
are expressed in normal cells, and if so, whether such expression imposes special restrictions on
cytotoxic T lymphocyte (CTL) responses. In this study, we use a transgenic approach to study
the development and effector function of T cells specific for P1A, a prototypical unmutated tu-
mor antigen. We report here that although P1A is expressed at low levels in normal tissues, in-
cluding lymphoid tissues, the P1A-specific transgenic T cells develop normally and remain
highly responsive to the P1A antigen. The fact that transgenic expression of P1A antigen in the
thymus induces T cell clonal deletion demonstrates that normal hematopoietic cells can process
and present the P1A antigen and that P1A-specific T cells are susceptible to clonal deletion. By
inference, P1A-specific T cells must have escaped clonal deletion due to low expression of P1A
in the thymus. Interestingly, despite the fact that an overwhelming majority of T cells in the T
cell receptor for antigen (TCR)–transgenic mice are specific for P1A, these mice are no more
resistant to a P1A-expressing plasmocytoma than nontransgenic littermates. Moreover, when
the same TCR-transgenic mice were challenged simultaneously with B7-1
 
1
 
 and B7-1
 
2
 
 tu-
mors, only B7-1
 
1
 
 tumors were rejected. Therefore, even though P1A can be a tumor rejection
antigen, the effector function of P1A-specific CTL is restrained in vivo. These results have im-
portant implications for the strategy of tumor immunotherapy.
Key words: cytotoxic T lymphocytes • unmutated tumor antigen • T cell development • 
antitumor immunity • T cell receptor–transgenic mice
 
A
 
fundamental question in tumor immunology is how
tumor antigens induce T cell responses. Even though
the existence of tumor antigens recognized by syngeneic T
cells has been well demonstrated (reviewed in reference 1),
the fundamental issue of whether these antigens are recog-
nized as self antigen or foreign antigen remains unresolved
(2, 3). Tumor antigens can be divided into two major cate-
gories: those that are mutated products of normal genes (4–
10) and those that bear no mutations (11–19). With the
notable exception of mutations in several oncogenes that
are directly responsible for tumorigenesis (4–7, 10), it is an-
ticipated that the mutated tumor antigens are usually
unique for individual tumors. Expression of unmutated tu-
mor antigens, on the other hand, has been demonstrated in
multiple tumors of the same lineage and among tumors of
multiple lineages (12–16, 20). It has been suggested that
this category of tumor antigens may offer valuable targets
for tumor vaccines (21).
The basic knowledge of vaccination is derived from our
experience with infectious agents, i.e., foreign antigens
(22). However, tumor antigens, particularly unmutated tu-
mor antigens, are not necessarily foreign to the immune
system. Of the unmutated tumor antigens identified so far,
genes encoding some of them, such as tyrosinase (23) and
Pmel 17 (18), are expressed in normal tissues. Other genes,
such as those for P1A in mice (11) and the MAGE and
GAGE families in humans (12–16), are reportedly ex-
pressed only on tumors or perhaps in immunologically
privileged sites such as testis (24, 25).
Multiple mechanisms have evolved to ensure self–non-
self discrimination of T cells. T cells specific for self antigen
in the thymus are deleted or rendered anergic (26, 27). In
the periphery, tissue-specific antigens can also inactivate T
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cells by either one of these mechanisms (28–31). It has
been documented that genes encoding a substantial number
of unmutated tumor antigens are expressed in normal cells,
but the immunological consequences have not been sys-
tematically analyzed. Two issues are particularly relevant.
First, If vaccines based on unmutated antigens induce
strong immunity, would such immune responses cause au-
toimmune disease? Although immunotherapy with tumor-
infiltrating lymphocytes specific for gp100 and vaccination
with GM–CSF-transduced renal carcinoma induced im-
mune reaction to normal tissues, neither procedure resulted
in severe autoimmune disease (2, 32, and 33). Immuniza-
tion with unmutated tumor antigen P1A, which is ex-
pressed in murine testis, does affect fertility in male mice
(24). Second, as self-reactive T cells are controlled at multi-
ple checkpoints during the development, induction, and
effector phase of T cell responses, it is of interest to deter-
mine if immune responses to unmutated tumor antigens are
restrained at any of these checkpoints.
P1A was the first unmutated tumor antigen to be identi-
fied. Although it was originally described in mastocytoma
cell lines (11), it was later observed that P1A is expressed in
testis (24), but expression in other tissues was not reported.
Using reverse transcriptase PCR (RT-PCR),
 
1
 
 we observed
that P1A is expressed at low but significant levels in nor-
mal tissue including hematopoietic tissues. To determine
whether unmutated tumor antigens can influence the de-
velopment, induction, and effector function of antigen-
specific T cells, we produced two types of transgenic mice:
one that expresses the T cell receptor from a CTL clone
that recognizes P1A, and another that overexpresses the tu-
mor antigen P1A in hematopoietic tissues. These mouse
models allowed us to monitor the effect of endogenous ex-
pression of tumor antigen on the development, induction,
and effector function of T cells specific for an unmutated
tumor antigen. Analysis of P1A-reactive T cells indicates
that endogenous P1A antigen does not interfere with the
development of P1A-specific T cells. Interestingly, the
TCR-transgenic mice are no more resistant than their lit-
termates to plasmacytoma J558. Moreover, even though
immunization with P1A peptide induces an anti-P1A CTL
response, it does not induce protection against P1A-
expressing tumors. Thus, although P1A-specific CTL de-
velop normally, their effector function is restrained in vivo.
 
Materials and Methods
 
Experimental Animals and Cell Lines.
 
BALB/cByJ, CByD2F1,
C3H/J, and C57BL/6j mice were purchased from The Jackson
Laboratory. Nude mice (nu/nu) were obtained from The Na-
tional Cancer Institute. 6–18-wk-old male mice were used for
the experiments. Plasmacytoma J558 was cultured in RPMI 1640
containing 5% FCS. J558 cells transfected with either pSR
 
a
 
(J558-Neo) or pSR
 
a
 
–
 
p
 
lnB7-1 (J558-B7) have been described
 
(34). Anti-P1A CTL line P1CTL (35) was provided by Dr.
Lieping Chen (Mayo Clinic, Rochester, MN).
 
Analysis of P1A Expression by RT-PCR.
 
Total RNA was iso-
lated from testis, liver, lung, spleen, and thymus of normal
BALB/c mice as well as J558 tumor cells. The first strand DNA
was prepared using GAATTCTCGAGTCTAGATTTTTTTTTT-
TTTTTTTTT as a primer. In brief, the reaction mixture con-
sisted of: 30 
 
m
 
l of total RNA (5 
 
m
 
g), 10 
 
m
 
l 5
 
3
 
 first strand buffer, 3
 
m
 
l 10 mM dNTP, 2 
 
m
 
l primer (100 
 
m
 
M), 2.5 
 
m
 
l H
 
2
 
O, and 2.5 
 
m
 
l
RT (GIBCO BRL). Reverse transcription reactions were carried
out at 42
 
8
 
C for 1 h. The RT was then inactivated by heating.
The first strand DNA was denatured at 96
 
8
 
C for 1 min, and the
P1A cDNA was then amplified by 40 cycles of PCR. Each cycle
consisted of: 94
 
8
 
C for 1.5 min, 55
 
8
 
C for 1.5 min, and 72
 
8
 
C for
2 min. The following primers were used. P1A: TGGCCTG-
GATAGCCAGGCAAAGCAAGCGCA as forward primer and
CTTCCGCTGTCCATTTCTTTCTTCTGGGCT as reverse
primer; glyceraldehyde 3-phosphate dehydrogenase (GAPDH):
ATGGTGAAGGTCGGTGTGAACGGATTTGGC as forward
primer and CATCGAAGGAAGAGTGGGAGTTGCTGT as
reverse primer. The P1A primers used should amplify a 500-bp
product from properly spliced P1A RNA. PCR product from
genomic DNA should be 3.1 kb. The size of amplifed GAPDH
cDNA should be 900 bp. The PCR products were separated on
agarose gels and then transferred onto nylon membrane as de-
scribed (36). P1A or GAPDH products were detected by 
 
32
 
P-
labeled specific probes.
 
Cytotoxic T Cell Assays.
 
Cytotoxic T cell line P1CTL (35)
specific for P1A35–43:L
 
d
 
 were used as effector cells and BALB/c
spleen cells that had been stimulated with LPS (10 
 
m
 
g/ml), Con
A (2 
 
m
 
g/ml), or anti-CD3 (0.25 
 
m
 
g/ml) for 48 h were used as
target cells. As control, P388D1 (H-2
 
d
 
) pulsed with 1 
 
m
 
g/ml of
P1A or control peptides were also used as targets. The lysis of tar-
get cells was determined by release of 
 
51
 
Cr after 6 h of coincuba-
tion with P1CTL. Data presented were specific lysis of target cells
calculated according to the following formula: Specific lysis % 
 
5
 
(cpm sample 
 
2
 
 cpm medium)/(cpm max 
 
2
 
 cpm medium) 
 
3
 
 100.
In other experiments, transgenic spleen cells were stimulated in
vitro for 3 d with 1 
 
m
 
g/ml of P1A peptide and used as effectors.
 
Production of P1A Transgenic Mice.
 
We designed synthetic oli-
gonucleotide primers corresponding to the ends of the P1A–open
reading frame; the forward primer contained a HindIII restriction
site and the reverse primer a ClaI site. These primers were used
to amplify the P1A–open reading frame from pBS–P1A. We used
the restriction sites at the end of the amplified fragment to clone
it into the E
 
m
 
mb–Id2 vector, a gift from Dr. Xiao-Hong Sun
(New York University Medical Center, New York) which con-
tains the IgM heavy chain enhancer (E
 
m
 
), the 
 
mb-1
 
-promoter, an in-
tron from the small T antigen gene, and an SV40 polyadenylation
signal (37). The construct was linearized by digestion with NotI,
and the fragment containing the P1A sequence was purified and
used for microinjection into fertilized eggs of (B6 
 
3
 
 D2)F1 origin.
 
Transgenic Mice Expressing TCR from a P1A-specific CTL Line.
 
Identification and cloning of the anti-P1A TCR and production
of transgenic mice follow the basic procedure established by
Kouskoff et al. (38). In brief, we cloned the VJ fragment of the
TCR 
 
a
 
 chain, and DNA sequencing confirmed that the CTL
line utilized V
 
a
 
8 and J10. We used linked PCR to generate a
PCR fragment containing the full length V
 
a
 
8 and J10 as well as a
small leading intronic sequence to ensure proper splicing of the
TCR mRNA. This fragment was then inserted into a PTR-
 
a
 
vector provided by Dr. Mathis (Institut de Génétique et de Bi-
ologie et Cellulaire, Strasburg, France; 38). Using published
 
1
 
Abbreviations used in this paper:
 
 E
 
m
 
, IgM heavy chain enhancer; GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; RT, reverse transcriptase;
SW, Swiss Webster; TG, transgenic mouse. 
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primer sequences, we found that P1CTL express only V
 
b
 
1, a 10-bp
D segment, J
 
b
 
2, and C
 
b
 
1. Transgenic vectors were produced as
described (38). After removing the prokaryote DNA sequences,
the transgenic vectors were injected into fertilized eggs from
Swiss Webster (SW) mice.
 
Proliferation of Transgenic T Cells.
 
To test whether antigen-
presenting spleen cells express P1A antigenic epitope, spleen
mononuclear cells from BALB/c mice were depleted of T cells
by two rounds of treatment with anti-Thy1.2 mAb plus comple-
ment. The T-depleted APC were cultured with either LPS (10
 
m
 
g/ml) or medium alone for 16 h; after five washes with PBS,
the viable spleen cells were irradiated for 2,000 rads and used as
stimulator cells (2 
 
3
 
 10
 
5
 
/well). T cells (6 
 
3
 
 10
 
4
 
/well) purified
from transgenic mice as described (36) were used as responders.
After 66 h, the cultures were pulsed with 
 
3
 
H-TdR (1.25 
 
m
 
Ci/
well) for 6 h. To test antigen specificity of the transgenic T cells,
we added varying concentrations of P1A peptide or control NP
peptide to 2 
 
3
 
 10
 
5
 
/well of transgenic or nontransgenic spleen
cells for 42 h and pulsed with 
 
3
 
H-TdR.
 
Tumorigenesis Assay.
 
Because the tumor cell lines used in this
study originated from BALB/c mice, we used mice that carried at
least one copy of the BALB/cByJ gene in all in vivo protection
experiments to avoid immune responses against minor histocom-
patibility antigens. In brief, transgenic founder SW mice were
crossed with BALB/cByJ mice for three generations, and the N2
mice were typed by flow cytometry for expression of the trans-
genic TCR-
 
a
 
 chain using PE-conjugated anti-V
 
a
 
8 mAb. Trans-
genic mice and their littermate controls were injected with 5 
 
3
 
10
 
6
 
 J558-B7 and J558-Neo subcutaneously in the left inguen. In
other experiments, both types of tumor cells were injected into
the same mice but on different sides. The tumor incidence was
recorded every other day. Palpable tumors with a diameter of 
 
.
 
3
mm were scored as positive.
 
Results
 
Tumor Antigen P1A Is Expressed at Low Levels in Normal
Tissue.
 
To determine if the P1A gene is expressed in nor-
mal tissues, we isolated RNA from a number of normal
mouse organs, including spleen, thymus, liver, lung, and
testis, and measured P1A mRNA by both Northern blot
and RT-PCR. Northern blot analysis did not reproducibly
detect significant levels of P1A RNA expression in most
tissues except in the testis (data not shown), which is con-
sistent with an earlier study by Uyttenhove et al. (24). We
therefore used the more sensitive method of RT-PCR to
detect the expression of P1A RNA. The PCR products
were detected by Southern blot using 
 
32
 
P-labeled probes.
This procedure not only ensured the identity of the prod-
ucts amplified but also enhanced the sensitivity of the assay.
The forward and reverse primers are in separate exons, and
the products amplified from genomic DNA should be 3.1 kb,
whereas those amplified from mRNA should be 500 bp. As
shown in Fig. 1 a, a significant amount of P1A RNA was
detected in most tissues by RT-PCR. The mRNA level
was highest in the testis as has been reported (24). Lung and
spleen tissues expressed more P1A RNA than liver tissue.
Although P1A RNA can be detected in the thymus in
some experiments, its thymic level was always at least 10-
fold lower than in the spleen (data not shown). To com-
pare the levels of P1A mRNA in spleen and tumor cells,
we titrated the amount of cDNA prepared from either
spleen or J558 tumor cells. As shown in Fig. 1 b, the rela-
tive abundance of the P1A cDNA in the spleen was 
 
z
 
100–
1,000-fold lower than levels found in the tumor cells.
We used a P1A:L
 
d
 
-specific CTL line, P1CTL, to deter-
mine if the P1A35–43:L
 
d
 
 epitope is presented on the normal
lymphoid cells. The P1CTL was generated after immuniza-
tion with P815 cells and has been restimulated in vitro for
almost two years (35). All cells in the P1CTL line express the
V
 
a
 
8 chain on cell surface (data not shown). As shown in Fig.
2 a, P1A-specific CTL failed to kill syngeneic spleen cells
that had been activated by either LPS, Con A, or anti-CD3
mAb. As a result we failed to detect P1A antigenic epitope
on activated T and B cells by CTL assay. However, since di-
rect cytolysis requires antigen expression on a substantial pro-
portion of target cells, this assay cannot rule out the possibil-
ity that a small proportion of cells may express the antigen.
We have recently produced transgenic mice that express
the TCR from P1CTL. We therefore used proliferation as-
say to determine if antigen-presenting spleen cells from syn-
geneic mice can induce activation of P1A-specific T cells. As
shown in Fig. 2 b, unstimulated spleen APC failed to induce
proliferation of transgenic T cells. However, after stimula-
tion with LPS, weak but significant proliferation of trans-
genic T cells could be detected. Thus, activated APC can
present P1A epitope. The relatively weak proliferation could
be due to either low frequency of APC that present P1A
epitope or a low level of P1A epitope expression on all APC.
Figure 1. Expression of un-
mutated tumor antigen. (a) Ex-
pression of P1A RNA in normal
tissues. Total RNA was isolated
from liver (Li), thymus (Th),
spleen (Sp), lung (Lu), and testis
(Te) of normal BALB/c mice,
and the expression of the P1A
gene was determined by RT-
PCR. The primers used detect a
0.5-kb fragment from mature
P1A RNA but a 3.1-kb fragment
from the genomic DNA.
GAPDH primers were used as a
control for the amount of cDNA
used in each sample. The sources
of RNA for different lanes are
indicated at the bottom. Note
that the autoradiograph of the
left four lanes was exposed for 4 h,
whereas that of the right two
lanes was exposed for 10 min. (b)
Comparison of the amounts of
P1A RNA in normal spleens and
J558 cells. First strand cDNA
prepared from 5 mg of total
RNA from either normal spleen
or J558 cells was suspended in 50
ml of water. 1, 0.1, 0.01, or
0.001  ml of the cDNA was used
as a template for PCR reaction using either P1A or GAPDH primers as
described in Materials and Methods. 20 ml of PCR products was sepa-
rated in agarose gels and the amount of specific products detected by
Southern blot. 
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Normal Development and Induction of P1A-specific CTL.
 
Given the fact that the P1A gene is expressed in hemato-
poietic cells, it is possible that endogenous expression of the
P1A gene may cause either clonal deletion or clonal anergy
of T cells. To analyze the development of P1A-specific T
cells, we cloned the T cell receptor from a P1A-specific
CTL line, P1A CTL. Using the cassette vector provided by
Kouskoff et al. (38), we produced mice with integration of
both 
 
a
 
 and 
 
b
 
 chains. Five independent founders were ob-
tained that have cointegration of 
 
a
 
 and 
 
b
 
 chains, three of
which are shown in Fig. 3 a. After breeding with BALB/c
mice, all F1 mice that carried the transgenes expressed V
 
a
 
chain on the surface of 
 
.
 
50% of PBL (Fig. 3 b). Lacking a
mAb specific for V
 
b
 
1, we were unable to directly measure
expression of the 
 
b
 
 chain; however, expression of the 
 
b
 
chains to which mAbs are available has been excluded, pre-
sumably due to transgenic expression of V
 
b
 
1 (data not
shown). To determine whether endogenous expression of
P1A impairs development of P1A-specific T cells, we ana-
lyzed the cellular composition of T cells in the thymus. As
shown in Fig. 3 c, the transgenic mice contain a large pro-
portion of CD4
 
1
 
CD8
 
1
 
 T cells and CD8
 
1
 
CD4
 
2
 
 T cells. A
skewing toward CD8
 
1
 
CD4
 
2
 
 subset is consistent with the
fact that transgenic TCR is restricted by MHC class I (39,
40). Moreover, essentially all CD8
 
1
 
CD4
 
2
 
 T cells in the
thymus express a high level of V
 
a
 
8 on the surface. These
results demonstrate that P1A-specific CD8
 
1
 
 T cells are not
subject to clonal deletion in normal mice.
To test whether endogenous P1A chronically stimulates
P1A-specific T cells, we measured expression of L-selectin
on T cells from the TCR-transgenic mice. L-selectin is ex-
pressed at a high level in naive T cells and is downregulated
upon T cell activation (41, 42). Because antigen-experi-
enced T cells remain L-selectin
 
low
 
 for a long period, this
phenotype has been used as a marker for antigenic expo-
sure of T cells. As shown in Fig. 3 d, spleen CD8 T cells
that expressed the transgenic 
 
a
 
 chain are of L-selectin
 
high
 
phenotype. In contrast, in the same spleen, a substantial
proportion of Va82 CD8 T cells is of L-selectinlow pheno-
type. These results demonstrated that the transgenic T cells
were not activated by the endogenous P1A antigen. This
conclusion is consistent with the fact that in vitro syngeneic
Figure 2. Detection of P1A:Ld
epitope in spleen cells by direct cy-
totoxicity assay (a) or proliferation
assay (b). (a) Direct cytotoxicity of
P1CTL to BALB/c spleen cells
which were activated by LPS,
Con A, or anti-CD3 mAb. Viable
cells were isolated, labeled with
51Cr, and used as target cells. Mac-
rophage P388D1 was pulsed with
either P1A (P1A) or an unrelated
Kd-binding peptide (KdP) and
used as control. (b) Proliferation of
transgenic T cells in response to
T-depleted spleen antigen–pre-
senting cells. T-depleted, BALB/c
spleen cells were cultured with ei-
ther medium or LPS for 16 h. Via-
ble cells were isolated by centrifu-
gation through a Ficoll-hypaque
medium, washed five times with
PBS, irradiated (2,000 rads), and
used as stimulator cells. Transgenic
spleen T cells from N2 of BALB/
cxSW TCR-TG founders were
used as responder. Data shown
were cpm incorporated by T cells
when stimulated with activated
APC (cpm[T1APC-A]) or resting
APC (cpm[T1APC-R]). Sum of cpmT (T cells cultured alone) plus cpm–
APC (APC cultured alone) was used as the negative control. Data shown
were means of six replicates and the standard deviations.
Figure 3. Endogenous expression
of unmutated tumor antigen does not
interfere with development of trans-
genic T cells expressing P1A-specific
TCR. (a) Cointegration of TCR a-
and  b-transgene in transgenic
founder mice. Tail DNA from 22 in-
dependent founder mice were
screened by PCR for integration of
transgenes, six of which are shown.
Top, integration of transgenes into
mouse tail genomic DNA. PCR re-
actions for the two chains were car-
ried out separately, but PCR prod-
ucts from the same mice were pooled
and analyzed in the same lane. Bot-
tom, the quality of the genomic
DNA is confirmed by similar amplifi-
cation of exon 3 of the PML gene.
(b) Expression of transgenic a chain among the TCR-transgenic (TCR-TG), nontransgenic (non-TG), or control PBL. PBL were either left unstained
(ctrl) or stained with FITC–labeled anti-Va8 mAb. (c) Development of transgenic T cells in BALB/c 3 TCR–TG F1 mice. Thymi from TCR-TG1
and TCR-TG2 mice were analyzed by three-color flow cytometry using FITC–anti-Va8, PE–anti-CD4, and cychrome–anti-CD8 mAbs. Data pre-
sented are expression of CD4 and CD8 coreceptors among total thymocytes (top) and expression of TCR a chain among CD81CD42 T cells (bottom).
(d) CD8 T cells in the spleen expressing transgenic TCR maintain naive phenotype. Spleen cells from TCR-TG mice were analyzed by three-color flow
cytometry using FITC–anti-Va8, PE–anti-CD62L, and cychrome–anti-CD8 mAbs. Data presented are histograms of PE channel among the CD81
Va82 (top) and CD81Va81 (bottom) cells. Numbers presented in the panels are percentages of cells that fall within the gate indicated.815 Sarma et al.
APC cannot stimulate transgenic T cells without LPS acti-
vation (Fig. 2 b).
To test whether the P1A-specific T cells are anergic, we
stimulated the spleen cells from P1A-transgenic mice and
their littermate controls with either P1A peptide or a con-
trol peptide from influenza virus. As shown in Fig. 4 a,
spleen cells from P1A-transgenic mice mounted a vigorous,
proliferative response to a low dose of P1A peptide. Maxi-
mal proliferation of T cells occurred with a dose of 10 ng/ml
of peptide, indicating that the transgenic TCR must have
high avidity for the tumor antigens. Moreover, after in
vitro restimulation, transgenic T cells exhibited strong cy-
totoxic activity against P1A-expressing plasmacytoma (Fig.
4 b). Interestingly, B7-11 tumor cells are more susceptible
than their B7-12 counterparts, which is consistent with
our previous observation of ex vivo, P1A-reactive CTL
(34). Since J558-B7 and J558-Neo expressed comparable
amounts of MHC class I (34) and P1A antigen (20), it is
likely that after 4 d of in vitro stimulation, the effector
function of transgenic T cells is dependent on B7 presence
on the target cells.
Clonal Deletion of P1A-specific T Cells in Transgenic Mice
Overexpressing P1A Gene in the Thymus. The lack of clonal
deletion and anergy of P1A-specific T cells is most likely
due to low expression of the P1A gene in hematopoietic
cells. We produced transgenic mice in which the expres-
sion of the P1A gene is under the control of mb-1 pro-
moter and Em enhancer. We prepared cDNA from total
thymic RNA and compared the amount of P1A mRNA in
normal versus transgenic thymus by titration of cDNA.
P1A mRNA was detectable in the thymi of transgenic
mice after the cDNA reached 1:270 dilution, whereas 1:10
dilution of cDNA from nontransgenic littermates failed to
yield any P1A product. Thus, P1A transgenic mice sig-
nificantly overexpressed P1A. In fact, the levels of P1A
mRNA in transgenic mice are comparable to those in J558
tumor cells (Fig. 5 a).
We bred the TCR-transgenic mouse (TG) with the
P1A-TG to generate TCR/P1A–TG and analyzed the cell
numbers and cell surface markers of TCR-TG and TCR/
P1A-TG thymi (Fig. 5 b). The total number of TCR/
P1A–TG thymocytes was z40% of that of TCR-TG (data
not shown). In addition, a discrete population of CD81
CD42 T cells in the TCR–TG is replaced by a population
of cells that has downregulated both CD4 and CD8 core-
ceptors. This progressive downregulation of CD8 receptors
is more obvious among the thymocytes that have expressed
the highest level of transgenic TCR. Moreover, the rela-
tive number of CD41CD81 T cells is greatly reduced, and,
as a result, an increase in the percentage of CD42CD82 T
cells is observed. These results demonstrate that P1A-spe-
cific T cells are being deleted in the TCR/P1A–TG. Con-
sequently, the CD81Va81 T cells are reduced by .80% in
Figure 4. Normal induction of P1A-specific transgenic T cells. (a) Pro-
liferation of spleen cells from transgenic and wild-type mice to tumor an-
tigen P1A peptide or control peptide from influenza virus nucleoprotein
(NP). (b) Cytotoxicity of transgenic T cells against J558-B7 or J558-Neo
tumor cells. P388D1 cells (H–2d) pulsed with either P1A or NP (1 mg/ml)
were used as controls. Transgenic spleen cells were stimulated for 72 h
with P1A peptide and used as effectors.
Figure 5. Clonal deletion of P1A-specific trans-
genic T cells in mice overexpressing P1A in the
thymus. (a) Overexpression of P1A mRNA in the
thymus of P1A-transgenic mice (P1A-TG) as com-
pared to that of nontransgenic mice (Non-TG).
cDNA, prepared from total mRNA of J558 tumor
cells, thymus P1A-TG, and Non-TG thymus, as
described in the Fig. 1 legend, were diluted 1:10,
1:30, 1:90, or 1:270. 1 ml of the cDNA from each
dilution was used for the PCR reaction. PCR prod-
ucts were transferred into nylon membrane, and the
identity of the PCR products verified by 32P-labeled
probes. The PCR products were not amplified from
genomic DNA, as no P1A can be amplified in the
absence of RT (data not shown). (b) Intrathymic
clonal deletion of transgenic T cells in mice overex-
pressing tumor antigen in the thymus. Thymocytes
(top) and spleen cells (bottom) from either TCR–TG
or TCR/P1A–TG mice were analyzed by two-
color flow cytometry for expression of CD4 vs.
CD8 or CD8 vs. Va8.816 Restraint in Anti-tumor CTL Effector Function
the TCR/P1A–TG compared to TCR-TG. Thus, trans-
genic T cells specific for unmutated tumor antigen are sus-
ceptible to clonal deletion in the thymus. Under normal
circumstances, these T cells must have escaped clonal dele-
tion because of low or no P1A expression in the thymus.
The Effector Function of P1A-specific CTL Is Restrained In
Vivo. To test whether the transgenic, P1A-specific cyto-
toxic T cells can efficiently reject the J558 tumor cells, we
bred the transgenic founder mice with BALB/cByJ for
three generations and tested the tumorigenicity of B7-
transfected (J558-B7) or vector-transfected (J558-Neo) tu-
mor cells in the N2 mice. Since all N2 mice carry at least
one copy of the BALB/c genes, minor histoincompatibility
should not cause tumor rejection. As shown in Table I, de-
spite the fact that an overwhelming majority of the T cells
in the transgenic mice express the P1A-specific T cell re-
ceptor, TCR-TG1 mice were no more resistant to the
plasmacytoma than their TCR-TG2 littermates. The rejec-
tion of J558-B7 is mediated by T cells, as J558-B7 and
J558-Neo gave similar tumor onset (not shown) and inci-
dences (Table I) in nu/nu mice.
As the J558-Neo tumor lacks costimulatory activity that
is essential for T cell activation, it is possible that lack of tu-
mor rejection is due to poor activation of the cytotoxic T
cells in vivo. To rule out this possibility, we injected J558-
B7 in the right inguens and J558-Neo in the left inguens of
the same mice and monitored the tumor incidence. As
shown in Table II, most of the mice that rejected J558-B7
tumors developed J558-Neo tumors. Both incidence (Ta-
ble II) and growth kinetics (data not shown) of the J558-
Neo tumor were unaffected by the J558-B7 injected into
the same mice. Thus, the failure of the TCR-TG mice to
reject J558-Neo tumors cannot be attributed to a lack of T
cell activation in vivo, and the results presented in this sec-
tion indicate that the effector function of the transgenic T
cell is restrained in vivo.
Discussion
Successful identification of tumor antigens marks the first
important step toward the development of tumor vaccines.
However, much of our current understanding of vaccina-
tion is based on experience with infectious agents that are
immunologically distinct from self antigens (22). Even
though such knowledge may be directly applicable to mu-
tated tumor antigens (4–10) that are, by definition, nonself,
a major issue is whether such approaches can be directly
applicable to unmutated antigens, many of which may turn
out to be self antigens (11–19). To address this important
issue, we used P1A as a model tumor antigen and took a
transgenic approach to study the development and effector
function of P1A-specific T cells. We have made two major
observations. First, endogenous expression of tumor anti-
gen does not interfere with the development and induction
of P1A-specific CTL. P1A was the first unmutated tumor
antigen to be identified. Although it was originally de-
scribed as expressed only in mastocytoma, later studies indi-
cated that it is expressed in testis (24) and in other lineages
of tumors (20). Here we used RT-PCR and were able to
reproducibly detect P1A mRNA in normal tissues, includ-
ing hematopoietic tissues. Two earlier studies based on
Northern blot analysis and RT-PCR analysis of P1A RNA
have concluded that in tissues other than testis, the level of
P1A mRNA is ,1% of that in P815 cells (24). Our finding
that P1A RNA in the spleen is z100-fold lower than that
of J558 tumor cells does not contradict findings in earlier re-
ports. Moreover, though resting APC fail to activate P1A-
specific T cells, significant proliferation of transgenic T cells
is induced by activated syngeneic APC. Nevertheless, P1A
is unlikely to be expressed on a large proportion of spleen
cells. If so, it would have been detected by CTL assay using
anti-P1A CTL, which generally requires less ligand but a
wider distribution of antigen among the target population
than is required for proliferation or IL-2 production (43).
Given the expression of the unmutated tumor antigen in
normal tissues, it is possible that a T cell repertoire specific
for such unmutated tumor antigens may have been selected
Table I. Transgenic Mice Rejected B7-11 but Not B7-12 J558 
Tumor Cells
Mice Tumors
Mice with tumors/
mice without tumors
TCR-TG1 J558-B7 0/3
J558-Neo 5/9
TCR-TG2 J558-B7 1/4
J558-Neo 4/8
nu/nu J558-B7 3/4
J558-Neo 3/4
N2 of BALB/cByJ 3 TCR2TG1 SW founder were screened for trans-
genic expression of the transgenic receptor by flow cytometry. Staining
with PE–conjugated anti-Va8 mAb revealed that z50% of PBL in the
TG1 mice expressed the Va8, whereas TG2 mice have ,2% of the
Va81 T cells in the PBL. 6–12-wk-old mice were inoculated in the left
inguen with 5 3 106 B7-11 (J558-B7) or B7-12 (J558-Neo) tumor
cells. Tumor incidences were determined by physical examination with
a 2–3-d interval. Data presented are tumor incidences at 25–27 d after
tumor cell inoculation.
Table II. Mice that Rejected B71 Tumors Did Not Reject
B72 Tumors
Mice
Mice with tumors/mice without tumors
Right inguen (J558-B7) Left inguen (J558-Neo)
TCR-TG1 0/7 4/7
TCR-TG2 1/6 4/6
The experiment was carried out as described in the Table I legend ex-
cept that the same mice were injected with J558-B7 in the right inguen
and J558-Neo in the left inguen.817 Sarma et al.
so that the high affinity TCR are eliminated as in the case
of T cells for some self antigens such as myelin basic protein
(44). Although this is an attractive hypothesis, clonal dele-
tion of T cells specific for unmutated tumor antigens has
not been directly addressed due to lack of an experimental
model. To our knowledge, this is the first report that has
evaluated clonal deletion of a transgenic TCR specific for a
natural tumor antigen. Our data clearly demonstrate that
despite expression in normal tissues, P1A product does
not induce clonal deletion of P1A-specific T cells. Since
the transgenic T cells require ,10 ng/ml of P1A peptide
for maximal proliferation, it is likely that the TCR–Ld/
P1A35–43 interaction is of high avidity. It follows that en-
dogenous P1A epitope does not cause clonal deletion of T
cells with high avidity for P1A:Ld complex, in contrast to
the epitope on myelin basic protein (44). Our conclusion is
supported by the fact that P1A-specific CTL clones charac-
terized by other researchers also have high avidity for the
peptide–Ld complex (39). Our results suggest that TCR
with high affinity for unmutated tumor antigen are not
eliminated from the T cell repertoire.
The transgenic T cells maintain a naive phenotype for
.6 mo (the age at which mice were killed for the study),
although a substantial proportion of T cells utilizing endog-
enous a chain have experienced antigenic stimulation from
the environment during the same period. It is therefore
most likely that the P1A epitope is essentially ignored by T
cells under physiological conditions. In this regard, it should
be emphasized that although P1A mRNA is detected in nor-
mal tissue, we have not analyzed expression of P1A protein
in these tissues due to lack of reagents. The P1A epitope is
detected on the spleen cells only after LPS activation.
Clonal deletion requires less TCR ligand than T cell ac-
tivation (45, 46). Lack of a discernible effect of endogenous
P1A on the development of P1A-specific T cells strength-
ens the conclusion that endogenous P1A epitope is not
present in significant amounts, particularly in the thymus.
Our second major observation was that the effector
function of P1A-reactive CTL is restrained in vivo. Four
lines of evidence strongly suggest that P1A can be a tumor
rejection antigen. First, classic studies by Uyttenhove et al.
reported that tumor cells that escaped immunity induced
by the tum2P815 had lost P1A antigen (47). Second, im-
munization with P1A cDNA induces protection against
subsequent challenge of P815 cells, although the authors
noticed that the correlation between the strength of the re-
call CTL response in vitro and the anti-tumor immunity
was poor (48). Third, adoptive transfer of P1A-specific
CTL line (35) or polyclonal CTL (49) protects against sub-
sequent challenge of P815 cells. Fourth, in mice challenged
with P815 tumor, a strong correlation was observed be-
tween expansion of recurrent TCR repertoire and tumor
rejection (50). Thus, although there is a strong case that
P1A can induce immunity against tumors that express the
antigen, it is less clear whether P1A-specific CTL gener-
ated in vivo are responsible for tumor rejection.
It is intriguing that active immunization with P1A, ei-
ther by adenoviruses engineered to express P1A in vivo
(49) or by P1A peptide (our unpublished results) which in-
duces anti-P1A CTL, does not confer immunity against
P1A-expressing tumors. In addition, we have previously
demonstrated that multiple lineages of tumors that share
the P1A antigen are not crossprotected (20). A critical issue
is whether the poor CTL-mediated protection is due to in-
sufficient clonal expansion of P1A-specific CD8 T cells or
to diminished effector function of these T cells. To address
this issue, we have produced transgenic mice in which the
overwhelming majority of CD8 T cells are specific for
P1A. We report here that unless B7-1 is present on the tu-
mor cells, no immunity is conferred by the cytotoxic T
cells. Moreover, when the same transgenic mouse is in-
jected with both B7-11 and B7-12 tumors, B71 tumors are
rejected but B7-12 tumors grow progressively. Our finding
supports and extends findings by Wick et al. (51), who
have recently reported that a tumor expressing an alloanti-
gen was not rejected in mice that carry transgenic T cells
specific for the antigen, although the same mice could re-
ject skin grafts with the same alloantigen. Even though
both studies highlight a restrained T cell effector function,
our study emphasized that such restriction can be over-
come by expressing B7-1 on the tumor cells.
Theoretically, at least four mechanisms can be proposed
to account for the apparent restraint of the effector func-
tion of P1A-specific CTL. First, T cells specific for unmu-
tated tumor antigen may be of intrinsically low affinity be-
cause high affinity P1A-reactive CTL may have been
deleted due to endogenous expression of the tumor anti-
gen. We show here that the high avidity, P1A-specific T
cells were not deleted, unless P1A is overexpressed in the
thymus as a transgene, which would rule out this possibil-
ity. Second, endogenous P1A may have rendered P1A-
reactive T cells anergic. This is also unlikely, as we have
shown that transgenic P1A-reactive T cells remain fully re-
sponsive to low concentrations of P1A and exhibit strong
cytotoxicity against P1A-expressing tumors after in vitro
stimulation. Third, it is possible that endogenous P1A has
prevented full maturation of P1A-reactive CTL. The fact
that fully active, P1A-specific CTL generated in vitro can
be therapeutic in vivo (35, 49) and that the effector func-
tion of ex vivo tumor-infiltrating lymphocytes recovered
from P1A-expressing tumors requires B7 on target cells for
optimal cytolysis (34) support this contention. Fourth, we
have recently demonstrated that anti-tumor CD8 T cells
do not exhibit cytotoxicity until after they have reached
the tumor site (52). The requirement of B7-1 for tumor re-
jection in the transgenic mice can also be explained in part
by the need for local activation of anti-tumor CTL.
Since tissue destruction by some autoreactive transgenic
T cells also requires expression of B7 in the target tissues
(53–55), it is tempting to suggest that endogenous expres-
sion of unmutated tumor antigen may contribute to the re-
strained effector function of transgenic T cells. This con-
cept can be formally tested when mice lacking endogenous
P1A are generated.
In summary, we have used a transgenic model to study
the development, induction, and effector function of P1A-818 Restraint in Anti-tumor CTL Effector Function
specific CTL. Our results demonstrate that the endogenous
P1A antigen does not cause clonal deletion of high avidity,
P1A-specific T cells in vivo. Even though P1A may well
be a tumor rejection antigen, the effector function of P1A-
specific T cells is restrained. Since P1A is the prototype of
unmutated tumor antigen, the findings presented here have
important implications: although this type of unmutated
antigen can be used as a target for tumor vaccines and tu-
mor immunotherapy, more emphasis must be placed on
the strategy to induce full activation of T cells to achieve
optimal effector function.
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